**Early-stage development timelines and the absence of Phase 3 efficacy trials drive the 95.5% market-implied probability of no FDA-approved hantavirus vaccine by December 31, 2026.** Leading candidates, including the Moderna-Korea University mRNA platform and UTMB single-dose mRNA constructs targeting Andes virus, remain in preclinical or initial Phase 1 testing following promising 2025–2026 animal data showing protection in rodent and hamster models. DNA and viral-vector candidates have completed only small early human immunogenicity studies, with no large-scale efficacy trials underway. The May 2026 MV Hondius outbreak heightened visibility and prompted calls for accelerated funding, yet standard regulatory pathways require substantial safety, immunogenicity, and efficacy data that cannot realistically be completed in the remaining months. Existing Hantavax formulations protect against certain Old World strains abroad but lack U.S. licensure. Unexpected emergency authorization or breakthrough trial acceleration could theoretically shift outcomes, though current surveillance shows contained transmission and no such regulatory moves.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% 概率
$135,595 交易量
$135,595 交易量
2026-12-31
5% 概率
$135,595 交易量
$135,595 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Early-stage development timelines and the absence of Phase 3 efficacy trials drive the 95.5% market-implied probability of no FDA-approved hantavirus vaccine by December 31, 2026.** Leading candidates, including the Moderna-Korea University mRNA platform and UTMB single-dose mRNA constructs targeting Andes virus, remain in preclinical or initial Phase 1 testing following promising 2025–2026 animal data showing protection in rodent and hamster models. DNA and viral-vector candidates have completed only small early human immunogenicity studies, with no large-scale efficacy trials underway. The May 2026 MV Hondius outbreak heightened visibility and prompted calls for accelerated funding, yet standard regulatory pathways require substantial safety, immunogenicity, and efficacy data that cannot realistically be completed in the remaining months. Existing Hantavax formulations protect against certain Old World strains abroad but lack U.S. licensure. Unexpected emergency authorization or breakthrough trial acceleration could theoretically shift outcomes, though current surveillance shows contained transmission and no such regulatory moves.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$135,595结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ETThis market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Early-stage development timelines and the absence of Phase 3 efficacy trials drive the 95.5% market-implied probability of no FDA-approved hantavirus vaccine by December 31, 2026.** Leading candidates, including the Moderna-Korea University mRNA platform and UTMB single-dose mRNA constructs targeting Andes virus, remain in preclinical or initial Phase 1 testing following promising 2025–2026 animal data showing protection in rodent and hamster models. DNA and viral-vector candidates have completed only small early human immunogenicity studies, with no large-scale efficacy trials underway. The May 2026 MV Hondius outbreak heightened visibility and prompted calls for accelerated funding, yet standard regulatory pathways require substantial safety, immunogenicity, and efficacy data that cannot realistically be completed in the remaining months. Existing Hantavax formulations protect against certain Old World strains abroad but lack U.S. licensure. Unexpected emergency authorization or breakthrough trial acceleration could theoretically shift outcomes, though current surveillance shows contained transmission and no such regulatory moves.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$135,595结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ET**Early-stage development timelines and the absence of Phase 3 efficacy trials drive the 95.5% market-implied probability of no FDA-approved hantavirus vaccine by December 31, 2026.** Leading candidates, including the Moderna-Korea University mRNA platform and UTMB single-dose mRNA constructs targeting Andes virus, remain in preclinical or initial Phase 1 testing following promising 2025–2026 animal data showing protection in rodent and hamster models. DNA and viral-vector candidates have completed only small early human immunogenicity studies, with no large-scale efficacy trials underway. The May 2026 MV Hondius outbreak heightened visibility and prompted calls for accelerated funding, yet standard regulatory pathways require substantial safety, immunogenicity, and efficacy data that cannot realistically be completed in the remaining months. Existing Hantavax formulations protect against certain Old World strains abroad but lack U.S. licensure. Unexpected emergency authorization or breakthrough trial acceleration could theoretically shift outcomes, though current surveillance shows contained transmission and no such regulatory moves.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题